Related Experiment Video
Updated: Aug 19, 2025
Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions
Jing Zhou1,2,3, Luohong Li1,2,3, Minqi Jia4
1NHC Key Laboratory of Carcinogenesis, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Introduction:
Gliomas, especially the glioblastomas, are one of the most aggressive intracranial tumors with poor prognosis. This might be explained by the heterogeneity of tumor cells and the inhibitory immunological microenvironment. Dendritic cells (DCs), as the most potent in vivo functional antigen-presenting cells, link innate immunity with adaptive immunity. However, their function is suppressed in gliomas. Therefore, overcoming the dysfunction of DCs in the TME might be critical to treat gliomas.
Method:
In this paper we proposed the specificity of the glioma microenvironment, analyzed the pathways leading to the dysfunction of DCs in tumor microenvironment of patients with glioma, summarized influence of DC-based immunotherapy on the tumor microenvironment and proposed new development directions and possible challenges of DC vaccines.
Result:
DC vaccines can improve the immunosuppressive microenvironment of glioma patients. It will bring good treatment prospects to patients. We also proposed new development directions and possible challenges of DC vaccines, thus providing an integrated understanding of efficacy on DC vaccines for glioma treatment.
Insights
Dendritic cell (DC) vaccines show promise for treating aggressive gliomas by improving the tumor microenvironment. This approach may overcome DC dysfunction and offer better treatment prospects for patients.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Research
Background:
- Gliomas, particularly glioblastomas, are aggressive intracranial tumors with poor prognoses.
- Tumor cell heterogeneity and an immunosuppressive microenvironment contribute to poor outcomes.
- Dendritic cells (DCs), crucial for linking innate and adaptive immunity, are functionally suppressed in the glioma tumor microenvironment (TME).
Purpose of the Study:
- To analyze the specificities of the glioma microenvironment.
- To investigate pathways causing DC dysfunction in glioma patients.
- To summarize the impact of DC-based immunotherapy on the TME and explore future directions for DC vaccines.
Main Methods:
- Analysis of the glioma tumor microenvironment.
- Investigation of dendritic cell (DC) dysfunction pathways.
- Review of DC-based immunotherapy strategies and DC vaccine development.
Main Results:
- Dendritic cell (DC) vaccines can enhance the immunosuppressive microenvironment in glioma patients.
- This immunotherapy approach offers potential for improved treatment outcomes.
- New development avenues and challenges for DC vaccines were identified.
Conclusions:
- Overcoming DC dysfunction in the TME is critical for effective glioma treatment.
- DC vaccines represent a promising therapeutic strategy for gliomas.
- Further research into DC vaccine development is warranted to address associated challenges.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...